13 Facts About Annie Luetkemeyer

Annie Luetkemeyer specializes in infectious diseases, in particular tuberculosis, human immunodeficiency virus and viral hepatitis.

Annie Luetkemeyer has researched treatment of COVID-19 as a co-infection with HIV.

Annie Luetkemeyer is the youngest of three sisters, one of whom is actress Julie Bowen.

In 1994, Annie Luetkemeyer received an AB with distinction in American Studies from Stanford University.

In 2002 and 2003, Annie Luetkemeyer trained in internal medicine at the University of California, San Francisco.

In 2012 Annie Luetkemeyer called for investigations into the doses of medications used for the treatment of HIV infection and tuberculosis.

Annie Luetkemeyer argued that the recommendations were not appropriate for all populations in the United States, and could result in more drug toxicity.

Annie Luetkemeyer is a member of the UCSF cross-campus COVID-19 task force.

In line with most official advice, Annie Luetkemeyer called for older people and those with preexisting conditions to be more careful during the outbreak, as the virus "taxes all organ systems".

Annie Luetkemeyer studied which COVID-19 patients were most likely to benefit from treatment, when during the illness was the best time for treatment, and which types of treatment were most appropriate.

Annie Luetkemeyer has outlined what pre- and post-exposure prophylaxis healthcare workers and household contacts can do to prevent disease spread.

Annie Luetkemeyer has called for more randomized controlled trials to assess the impact of hydroxychloroquine.

Annie Luetkemeyer led a clinical trial of the drug remdesivir with other researchers like Sarah Pett.